Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Current Deferred Revenue (2016 - 2020)

Aytu Biopharma (AYTU) has disclosed Current Deferred Revenue for 6 consecutive years, with $475680.0 as the latest value for Q4 2020.

  • On a quarterly basis, Current Deferred Revenue changed N/A to $475680.0 in Q4 2020 year-over-year; TTM through Dec 2020 was $475680.0, a N/A change, with the full-year FY2020 number at $339336.0, changed N/A from a year prior.
  • Current Deferred Revenue was $475680.0 for Q4 2020 at Aytu Biopharma, up from $232576.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $475680.0 in Q4 2020 to a low of $1450.0 in Q2 2018.
  • A 4-year average of $145070.9 and a median of $13990.0 in 2018 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: surged 397.0% in 2016, then tumbled 98.43% in 2017.
  • Aytu Biopharma's Current Deferred Revenue stood at $426000.0 in 2016, then crashed by 98.88% to $4787.0 in 2017, then skyrocketed by 192.25% to $13990.0 in 2018, then soared by 3300.14% to $475680.0 in 2020.
  • Per Business Quant, the three most recent readings for AYTU's Current Deferred Revenue are $475680.0 (Q4 2020), $232576.0 (Q3 2020), and $339336.0 (Q2 2020).